Arbaclofen placarbil
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | 847353-30-4 |
| PubChem (CID) | 11281011 |
| ChemSpider | 9456008 |
| KEGG |
D08861  Y |
| ChEMBL |
CHEMBL2107312 Y |
| Chemical and physical data | |
| Formula | C19H26ClNO6 |
| Molar mass | 399.86 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Arbaclofen placarbil (ar-BAC-loe-fen pla-KAR-bil, also known as XP19986) is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.[1]
See also
References
Skeletal muscle relaxants (M03) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peripherally acting (primarily antinicotinic, NMJ block) |
| ||||||||||||||||
| Centrally acting | |||||||||||||||||
| Directly acting | |||||||||||||||||
| H2 antagonists ("-tidine") | |
|---|---|
| Prostaglandins (E)/analogues ("-prost-") | |
| Proton-pump inhibitors ("-prazole") |
|
| Potassium-competitive acid blockers ("-prazan") |
|
| Others | |
| Combinations | |
| Calcium (Ca2+) |
| ||||||
|---|---|---|---|---|---|---|---|
| Potassium (K+) |
| ||||||
| Sodium (Na+) |
| ||||||
| Chloride (Cl−) |
| ||||||
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.